• news.cision.com/
  • Elekta/
  • GenesisCare orders Elekta Unity MR-linac to increase access to cutting edge cancer treatment

GenesisCare orders Elekta Unity MR-linac to increase access to cutting edge cancer treatment

Report this content

Australia’s largest provider of radiotherapy treatment continues its leadership in bringing state-of-the-art technology into mainstream cancer therapy to improve patient outcomes

SYDNEY, August 24, 2018 – Elekta (EKTA-B.ST) today announced that GenesisCare, the largest private provider of cancer treatment in Australia and Europe, has placed an order for Elekta’s magnetic resonance radiation therapy (MR/RT) system, Elekta Unity.

GenesisCare Executive Manager of Oncology, Keith Hansen, said: “This is a paradigm shift for radiotherapy. The new MR-linac will allow us to see soft tissue during treatment with unprecedented accuracy. In real-time we’ll be able to track the tumor, and also any movement of organs at risk, to further minimize a patient’s side effects. The added visibility of the MRI will also enable us to treat regions that have been difficult to treat before.

“This is a very exciting innovation in the evolution of radiotherapy, and a great example of re-designing a care experience to get the best possible life outcomes for our patients. We’re thrilled to be partnering with Elekta to increase access to what will be one of Australia’s first clinical MR-linacs used to treat patients, and look forward to delivering our first treatments using this cutting-edge technology from mid-2019.”

“It is estimated that nearly 140,000 new cancer cases will be diagnosed in Australia in 2018 alone, and that there will be nearly 50,000 cancer deaths in the same period,” said Richard Hausmann, Elekta President and Chief Executive Officer. “We are proud of the contributions that Elekta products, software and services have made to advance the care of Australian cancer patients, and we are gratified that GenesisCare is helping to achieve our shared vision of making innovative technologies available to patients who may benefit from them.”

GenesisCare has developed a world-class model for cancer care that is designed to improve healthcare quality and access by ensuring patients receive the right care when needed, continuously finding ways to capture and monitor patient outcomes and providing better support to the people looking after patients. Consistent with this model, GenesisCare fosters the sharing of best practices around technology, training, clinical practice, process and systems to facilitate integrated care delivery.

To learn more, visit elekta.com/Unity.

Elekta Unity is listed in the Australian Register of Therapeutic Goods and Medsafe New Zealand, has CE mark and is pending FDA 510(k) premarket clearance, but not available for commercial distribution or sale in the U.S. 

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: 
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

Lauren Coleman, GenesisCare Communications Manager
Tel: +61 413 254 545, e-mail: Lauren.Coleman@genesiscare.com
Time zone: AEST: Australian Eastern Daylight Time

About Elekta Unity
Elekta Unity combines high-field 1.5 Tesla MR imaging, precision radiation therapy and intelligent software, allowing clinicians to see what they treat in real time. As a result, Elekta Unity is the only system that truly addresses a critical unmet need in cancer therapy: visualizing and tracking the tumor with crystal-clear differentiation from soft tissue anatomies during treatment and adapting treatment in real time to account for changes in the position of the tumor and nearby healthy tissue. This enables personalized, precision therapy for each patient and every treatment session.

About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.

About GenesisCare
GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. We’re committed to leading the change in how care is designed and given, and are currently leading or participating in more than 100 clinical trials.

The organisation employs more than 2,500 highly trained health professionals and support staff across Australia, the U.K. and Spain, including some of the world’s most experienced specialists. Every year our teams see more than 160,000 people at more than 130 locations. For radiation therapy, that includes 12 centres in the UK, 21 in Spain and 30 in Australia, with more than 10 new centres under development. We also offer cardiology and sleep services at more than 80 locations across Australia.

Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our patient satisfaction ratings, which place us in the top 1 per cent of outpatient healthcare organisations in the world.


Documents & Links


This is a paradigm shift for radiotherapy. The new MR-linac will allow us to see soft tissue during treatment with unprecedented accuracy.
Keith Hansen, Executive Manager of Oncology, GenesisCare